VEGFA and renal cell carcinoma: Since then, several other specific agents against VEGF, PDGF, and their receptors have been approved for the treatment of RCC, including sunitinib, axitinib, cabozanitinib, lenvatinib, pazopanib, and bevacizumab (Dizman et al., 2020).